UB Paderborn / Katalog / Suche / in CDI

282. Transient Adenoviral Methylpurine DNA Glycosylase Overexpression Imparts Chemotherapeutic Sensitivity to Human Breast Cancer Cells

Molecular therapy, 2004-05, Vol.9 (S1), p.S108-S108

2004

Link zum Volltext

Verfügbarkeit prüfen

439 Dual modes of action for anti-TIM-3 antibody MBG453 in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML): preclinical evidence for immune-mediated and anti-leukemic activity

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A267-A267

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4974: Pharmacogenomic interactions in glioblastoma cell line models

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.4974-4974

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract B077: Comprehensive molecular characterization and high-throughput chemical screening identifies genetic dependencies and molecular vulnerabilities in glioblastoma cell line models

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.B077-B077

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT3-23-01: VELA: A first-in-human phase 1/2 study of BLU-222, a potent, selective cyclin-dependent kinase (CDK) 2 inhibitor in patients with cyclin E1 gene (CCNE1)-amplified or CDK4/6 inhibitor-resistant advanced solid tumors

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.OT3-23-01-OT3-23-01

2023

Link zum Volltext

Verfügbarkeit prüfen

ACTR-93. A PHASE I STUDY OF MLN0128 (TAK-228) AND BEVACIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS INCLUDING GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2017-11, Vol.19 (suppl_6), p.vi20-vi21

2017

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma

Neuro-oncology (Charlottesville, Va.), 2014-11, Vol.16 (11), p.1547-1553

2014

Link zum Volltext

Verfügbarkeit prüfen

Altering DNA base excision repair: Use of nuclear and mitochondrial-targeted N-methylpurine DNA glycosylase to sensitize astroglia to chemotherapeutic agents

Glia, 2007-11, Vol.55 (14), p.1416-1425

2007

Link zum Volltext

Verfügbarkeit prüfen

Amino Acids Important for Ligand Specificity of the Human Constitutive Androstane Receptor

The Journal of biological chemistry, 2005-02, Vol.280 (7), p.5960-5971

2005

Link zum Volltext

Verfügbarkeit prüfen

AML-190: Anti-TIM-3 Antibody MBG453 in Combination with Hypomethylating Agents (HMAs) in Patients with High-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia: A Phase 1 Study

Clinical lymphoma, myeloma and leukemia, 2020-09, Vol.20, p.S188-S189

2020

Link zum Volltext

Verfügbarkeit prüfen

Amyloid and tau proteins in cortical brain biopsy and Alzheimer's disease

Annals of neurology, 2010-10, Vol.68 (4), p.446-453

2010

Link zum Volltext

Verfügbarkeit prüfen

Amyloid-β and Tau Dynamics in Human Brain Interstitial Fluid in Patients with Suspected Normal Pressure Hydrocephalus

Journal of Alzheimer's disease, 2015-01, Vol.46 (1), p.261

2015

Link zum Volltext

Verfügbarkeit prüfen

An Approach to Realizing Process Control for Underground Mining Operations of Mobile Machines

PloS one, 2015-06, Vol.10 (6), p.e0129572-e0129572

2015

Link zum Volltext

Verfügbarkeit prüfen

AT-36 PANOBINOSTAT IN COMBINATION WITH BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA AND ANAPLASTIC GLIOMA

Neuro-oncology (Charlottesville, Va.), 2014-11, Vol.16 (suppl 5), p.v16-v16

2014

Link zum Volltext

Verfügbarkeit prüfen

AT-36PANOBINOSTAT IN COMBINATION WITH BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA AND ANAPLASTIC GLIOMA

Neuro-oncology (Charlottesville, Va.), 2014-11, Vol.16 (suppl_5), p.v16-v16

2014

Link zum Volltext

Verfügbarkeit prüfen

ATNT-18A PHASE I STUDY OF MLN0128 AND BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA AND OTHER SOLID TUMORS

Neuro-oncology (Charlottesville, Va.), 2015-11, Vol.17 (suppl 5), p.v14.3-v14

2015

Link zum Volltext

Verfügbarkeit prüfen

AZURE: A Phase 1/2 Study of Blu-263 As Monotherapy and in Combination with Azacitidine in Patients with Advanced Systemic Mastocytosis

Blood, 2022-11, Vol.140 (Supplement 1), p.6877-6878

2022

Link zum Volltext

Verfügbarkeit prüfen

BLU-222, an oral, potent, and selective CDK2 inhibitor, in patients with advanced solid tumors: Phase 1 monotherapy dose escalation

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3095-3095

2023

Link zum Volltext

Verfügbarkeit prüfen

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial

Journal of clinical oncology, 2019-03, Vol.37 (9), p.741-750

2019

Link zum Volltext

Verfügbarkeit prüfen

Cell-free tumor DNA and TERT promoter mutations in bladder cancer

Journal of clinical oncology, 2017-02, Vol.35 (6_suppl), p.353-353

2017

Link zum Volltext

Verfügbarkeit prüfen

The Center of Excellence in Atmospheric Science (2002–2019) — from molecular and biological processes to the global climate

Boreal environment research, 2023, Vol.28 (1-6), p.15

2023

Link zum Volltext

Verfügbarkeit prüfen

Central nervous system complications of cancer therapy

The Journal of supportive oncology, 2012-07, Vol.10 (4), p.133

2012

Link zum Volltext

Verfügbarkeit prüfen

Central nervous system involvement by Waldenström macroglobulinaemia (Bing‐Neel syndrome): a multi‐institutional retrospective study

British journal of haematology, 2016-03, Vol.172 (5), p.709-715

2016

Link zum Volltext

Verfügbarkeit prüfen

Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor

Immunotherapy advances, 2022-01, Vol.2 (1), p.ltac019-ltac019

2022

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

282. Transient Adenoviral Methylpurine DNA Glycosylase Overexpression Imparts Chemotherapeutic Sensitivity to Human Breast Cancer Cells

439 Dual modes of action for anti-TIM-3 antibody MBG453 in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML): preclinical evidence for immune-mediated and anti-leukemic activity

Abstract 4974: Pharmacogenomic interactions in glioblastoma cell line models

Abstract B077: Comprehensive molecular characterization and high-throughput chemical screening identifies genetic dependencies and molecular vulnerabilities in glioblastoma cell line models

Abstract OT3-23-01: VELA: A first-in-human phase 1/2 study of BLU-222, a potent, selective cyclin-dependent kinase (CDK) 2 inhibitor in patients with cyclin E1 gene (CCNE1)-amplified or CDK4/6 inhibitor-resistant advanced solid tumors

Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results

ACTR-93. A PHASE I STUDY OF MLN0128 (TAK-228) AND BEVACIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS INCLUDING GLIOBLASTOMA

Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma

Altering DNA base excision repair: Use of nuclear and mitochondrial-targeted N-methylpurine DNA glycosylase to sensitize astroglia to chemotherapeutic agents

Amino Acids Important for Ligand Specificity of the Human Constitutive Androstane Receptor

AML-190: Anti-TIM-3 Antibody MBG453 in Combination with Hypomethylating Agents (HMAs) in Patients with High-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia: A Phase 1 Study

Amyloid and tau proteins in cortical brain biopsy and Alzheimer's disease

Amyloid-β and Tau Dynamics in Human Brain Interstitial Fluid in Patients with Suspected Normal Pressure Hydrocephalus

An Approach to Realizing Process Control for Underground Mining Operations of Mobile Machines

AT-36 PANOBINOSTAT IN COMBINATION WITH BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA AND ANAPLASTIC GLIOMA

AT-36PANOBINOSTAT IN COMBINATION WITH BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA AND ANAPLASTIC GLIOMA

ATNT-18A PHASE I STUDY OF MLN0128 AND BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA AND OTHER SOLID TUMORS

AZURE: A Phase 1/2 Study of Blu-263 As Monotherapy and in Combination with Azacitidine in Patients with Advanced Systemic Mastocytosis

BLU-222, an oral, potent, and selective CDK2 inhibitor, in patients with advanced solid tumors: Phase 1 monotherapy dose escalation

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial

Cell-free tumor DNA and TERT promoter mutations in bladder cancer

The Center of Excellence in Atmospheric Science (2002–2019) — from molecular and biological processes to the global climate

Central nervous system complications of cancer therapy

Central nervous system involvement by Waldenström macroglobulinaemia (Bing‐Neel syndrome): a multi‐institutional retrospective study

Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor

Suchergebnisse filtern